April, 2024
April 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Shubh Goel: Recently, I spoke to a Pharmaceutical Executive following data presented at ASCO GI from our EMERALD-1 and MATTERHORN Phase III trials
Feb 27, 2024, 05:27

Shubh Goel: Recently, I spoke to a Pharmaceutical Executive following data presented at ASCO GI from our EMERALD-1 and MATTERHORN Phase III trials

Shubh Goel, VP and US Franchise Head, Immuno-Oncology and GI Tumors at

“This post is intended for a US audience. Recently, I spoke to a Pharmaceutical Executive following data presented at ASCO GI from our EMERALD-1 and MATTERHORN Phase III trials, in liver cancer and gastric cancer, respectively.

At AstraZeneca, we believe if we can intervene earlier, we have a better chance of improving long-term outcomes for patients, so it was great to share more about our extensive clinical development program to treat GI cancers earlier. Thanks for chatting with me, Donald Tracy!”

Read further.

Source: Shubh Goel/LinkedIn